Clinical trials: Hypertrophic
Hypertrophic Scar, Keloid Scar
A Substantial Equivalence Study of RD04723 and Predicate Device
The purpose of this study is to determine whether a developmental formulation is substantially equivalent to the predicate device in the treatment of hypertrophic and keloid scars.
- Trial name
- NCT01736969
- Testing
- RD047-023, Predicate Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oculus Innovative Sciences, Inc.
Prostate
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.
- Trial name
- NCT00648323
- Testing
- Doxazosin mysylate GITS
- Where
- 4 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bilateral Vocal Cord Paralysis
Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients Without Glottal Enlargement
The goal of this clinical investigation is to learn about the use of a novel medical device, the SPIRION Laryngeal Pacemaker, in patients suffering from bilateral vocal fold paralysis (BVFP).
- Trial name
- NCT06007170
- Testing
- SPIRION Laryngeal Pacemaker System Implantation and follow-up
- Where
- 6 sites in Austria, Germany
- Volunteers
- 20 people
- Sponsor
- MED-EL Elektromedizinische Geräte GmbH
Pneumothorax, Pulmonary Nodule, Solitary
Multi-Reader Retrospective Study Examining Carebot AI CXR 2.0.21-v2.01 Implementation in Everyday Radiology Clinical Practice
The primary objective is to evaluate the performance parameters of the proposed DLAD (Carebot AI CXR) in comparison to individual radiologists.
- Conditions
- Pneumothorax, Pulmonary Nodule, Solitary, Atelectasis, Subcutaneous Emphysema
- Trial name
- NCT05963945
- Testing
- Carebot AI CXR
- Where
- Czechia
- Volunteers
- 956 people
- Sponsor
- Carebot s.r.o.
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
This is a pilot study of the Flow Medical Catheter, a catheter-based device used to deliver clot-dissolving medication directly to a blood clot in the lungs (pulmonary embolism).
- Trial name
- PE (NCT07681154)
- Testing
- Thrombolysis Catheter
- Volunteers
- 20 people
- Sponsor
- Flow Medical Solutions, Inc.
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PAC326 (NCT02055781)
- Testing
- Pacritinib, Best Available Therapy
- Where
- 122 sites in United States, Australia and 10 more
- Volunteers
- 311 people
- Sponsor
- CTI BioPharma
Facial Subcutaneous Fat, Facial Erythema
Efficacy and Safety of Overnight Occlusive HA35 Gel for Facial Aesthetic Improvement
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of overnight occlusive topical application of 10% high-concentration 35 kDa hyaluronan (HA35) gel for facial aesthetic…
- Conditions
- Facial Subcutaneous Fat, Facial Erythema, Skin Dullness, Nasal Alar Pore Enlargement
- Trial name
- HA35-FACIAL (NCT07584811)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Facial Occlusive Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC
Hypertrophic Scar
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.
- Trial name
- NCT02030275
- Testing
- RXI-109
- Where
- 5 sites in United States, Honduras
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Prostatic Hyperplasia
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
Patients who are currently symptomatic and have been diagnosed with BPH by a physician may qualify for this 20-week study. Patients must not be diabetic, must not have prostate cancer and must not have had any surgery to repair…
- Trial name
- NCT00044226
- Testing
- ML-04A
- Where
- 14 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Milkhaus Laboratory
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Acceptability Study, Real-use Conditions
Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars
Evaluation of the safety and topical efficacy of a scar gel after 90 days of continuous use, comparing it to a benchmark for preventing hypertrophic scars and improving appearance, hydration and pigmentation.
- Conditions
- Acceptability Study, Real-use Conditions, Safety and Efficacy, Topical Administration
- Trial name
- NCT06751433
- Testing
- Scar gel, Scar gel comparator
- Where
- 2 sites in Brazil
- Volunteers
- 80 people
- Sponsor
- Herbarium Laboratorio Botanico Ltda
Acne Scars - Mixed Atrophic and Hypertrophic
Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.
The ClearSkin module, Er: Glass 1540nm, is largely used in the treatment of acne vulgaris and acne scars. The non-ablative ER:Glass 1540 nm laser deeply penetrates the skin, causing thermal damage to the sebaceous glands…
- Trial name
- NCT06102343
- Testing
- Alma Harmony
- Where
- Portugal
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Alma Lasers
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Developmental Delay, Skeletal Abnormalities
Biomarker for Sly Disease (MPS VII) (BioSly)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
- Conditions
- Developmental Delay, Skeletal Abnormalities, Hepatomegaly, Splenomegaly
- Trial name
- BioSly (NCT02298699)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Labia Enlarged, Labium; Hypertrophy
Evaluation of the Use of the Renuvion APR System in the Labia
Labiaplasty is a procedure aimed at reducing lax or loose skin in the labia majora and/or minora due to childbirth, trauma, aging, genetics, or congenital disease.
- Trial name
- NCT05323630
- Testing
- Renuvion APR System
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Apyx Medical
Non-obstructive Hypertrophic Cardiomyopathy
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2…
- Trial name
- MAVERICK-HCM (NCT03442764)
- Testing
- mavacamten
- Where
- 32 sites in United States
- Volunteers
- 59 people
- Sponsor
- MyoKardia, Inc.
Hypertrophic Cardiomyopathy, Obstructive
REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
This is a prospective, multicenter, randomized, parallel-controlled, superiority clinical trial designed to evaluate the efficacy and safety of a transcatheter intramyocardial septal radiofrequency ablation system for the…
- Trial name
- REFINE-HCM (NCT07006493)
- Testing
- Transcatheter Intramyocardial Septal Radiofrequency Ablation System
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- SuZhou Sinus Medical Technologies Co.,Ltd
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Hypertrophic Scars, Keloids
CICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars
The purpose of the study is to assess the efficacy of CICATRIX (Asian Gotu Kola or Pennywort) usage in the treatment of Hypertrophic scars and keloids.
- Trial name
- NCT00993005
- Testing
- Cicatrix
- Where
- Cuba
- Volunteers
- 90 people
- Sponsor
- Catalysis SL
Benign Masseteric Hypertrophy
Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy
This study is A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric Hypertrophy
- Trial name
- NCT04443244
- Testing
- Botulinum Toxin Type A Injection (Botulax®) 24Units, Botulinum Toxin Type A Injection (Botulax®) 48Units, Botulinum Toxin Type A Injection (Botulax®) 72Units
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Hugel